

**PHARMACEUTICAL TURNOVER**  
**Three months ended 30th June 2006**

|                                      | Total        |            |             | USA          |             |             | Europe       |             |             | International |            |             |
|--------------------------------------|--------------|------------|-------------|--------------|-------------|-------------|--------------|-------------|-------------|---------------|------------|-------------|
|                                      | £m           | CER%       | £%          | £m           | CER%        | £%          | £m           | CER%        | £%          | £m            | CER%       | £%          |
| <b>RESPIRATORY</b>                   | <b>1,232</b> | <b>-</b>   | <b>1</b>    | <b>582</b>   | <b>(4)</b>  | <b>(4)</b>  | <b>441</b>   | <b>3</b>    | <b>5</b>    | <b>209</b>    | <b>10</b>  | <b>11</b>   |
| <i>Seretide/Advair</i>               | 822          | 12         | 13          | 453          | 13          | 14          | 293          | 10          | 13          | 76            | 12         | 10          |
| <i>Flixotide/Flovent</i>             | 164          | 2          | 3           | 69           | 8           | 8           | 45           | (8)         | (6)         | 50            | 4          | 6           |
| <i>Serevent</i>                      | 74           | (13)       | (13)        | 21           | (19)        | (19)        | 36           | (16)        | (16)        | 17            | 6          | 6           |
| <i>Flixonase/Flonase</i>             | 68           | (53)       | (54)        | 34           | (68)        | (70)        | 17           | (11)        | (11)        | 17            | -          | 6           |
| <b>CENTRAL NERVOUS</b>               | <b>918</b>   | <b>18</b>  | <b>19</b>   | <b>644</b>   | <b>35</b>   | <b>37</b>   | <b>152</b>   | <b>(18)</b> | <b>(16)</b> | <b>122</b>    | <b>5</b>   | <b>4</b>    |
| <i>Seroxat/Paxil</i>                 | 159          | 5          | 4           | 40           | 40          | 33          | 38           | (19)        | (19)        | 81            | 7          | 7           |
| <i>Paxil IR</i>                      | 122          | (1)        | (3)         | 8            | 50          | 33          | 38           | (17)        | (17)        | 76            | 5          | 3           |
| <i>Paxil CR</i>                      | 37           | 33         | 37          | 32           | 38          | 33          | -            | -           | -           | 5             | 50         | >100        |
| <i>Wellbutrin</i>                    | 237          | 40         | 42          | 232          | 39          | 41          | -            | -           | -           | 5             | >100       | >100        |
| <i>Wellbutrin IR, SR</i>             | 27           | >100       | >100        | 24           | >100        | >100        | -            | -           | -           | 3             | >100       | >100        |
| <i>Wellbutrin XL</i>                 | 210          | 34         | 36          | 208          | 34          | 36          | -            | -           | -           | 2             | 100        | 100         |
| <i>Imigran/Imitrex</i>               | 175          | 7          | 8           | 134          | 19          | 20          | 30           | (19)        | (19)        | 11            | (23)       | (15)        |
| <i>Lamictal</i>                      | 245          | 12         | 13          | 186          | 31          | 33          | 46           | (27)        | (26)        | 13            | (7)        | (7)         |
| <i>Requip</i>                        | 64           | 85         | 88          | 41           | >100        | >100        | 20           | 18          | 18          | 3             | 50         | 50          |
| <b>ANTI-VIRALS</b>                   | <b>719</b>   | <b>12</b>  | <b>13</b>   | <b>344</b>   | <b>11</b>   | <b>13</b>   | <b>218</b>   | <b>7</b>    | <b>10</b>   | <b>157</b>    | <b>21</b>  | <b>21</b>   |
| <b>HIV</b>                           | <b>393</b>   | <b>1</b>   | <b>2</b>    | <b>182</b>   | <b>(5)</b>  | <b>(3)</b>  | <b>163</b>   | <b>1</b>    | <b>4</b>    | <b>48</b>     | <b>24</b>  | <b>14</b>   |
| <i>Combivir</i>                      | 141          | (6)        | (5)         | 63           | (11)        | (10)        | 58           | (3)         | (3)         | 20            | 6          | 11          |
| <i>Trizivir</i>                      | 72           | (5)        | (4)         | 38           | (5)         | (5)         | 29           | (9)         | (9)         | 5             | 33         | 67          |
| <i>Eпивir</i>                        | 53           | (25)       | (22)        | 18           | (29)        | (25)        | 25           | (27)        | (24)        | 10            | (9)        | (9)         |
| <i>Ziagen</i>                        | 29           | (19)       | (19)        | 12           | (20)        | (20)        | 10           | (38)        | (38)        | 7             | 40         | 40          |
| <i>Agenerase, Lexiva</i>             | 32           | 23         | 23          | 18           | 13          | 13          | 12           | 50          | 50          | 2             | -          | -           |
| <i>Epzicom/Kivexa</i>                | 58           | >100       | >100        | 32           | 72          | 78          | 23           | >100        | >100        | 3             | >100       | >100        |
| <b>Herpes</b>                        | <b>245</b>   | <b>25</b>  | <b>26</b>   | <b>151</b>   | <b>39</b>   | <b>41</b>   | <b>36</b>    | <b>3</b>    | <b>6</b>    | <b>58</b>     | <b>9</b>   | <b>7</b>    |
| <i>Valtrex</i>                       | 214          | 30         | 32          | 149          | 39          | 41          | 28           | 13          | 17          | 37            | 16         | 16          |
| <i>Zovirax</i>                       | 31           | (3)        | (6)         | 2            | 100         | 100         | 8            | (20)        | (20)        | 21            | -          | (5)         |
| <i>Zeffix</i>                        | 40           | 5          | 8           | 3            | -           | -           | 6            | (14)        | (14)        | 31            | 11         | 15          |
| <i>Relenza</i>                       | 17           | >100       | >100        | -            | -           | -           | 10           | -           | -           | 7             | >100       | >100        |
| <b>METABOLIC</b>                     | <b>529</b>   | <b>32</b>  | <b>35</b>   | <b>372</b>   | <b>37</b>   | <b>39</b>   | <b>61</b>    | <b>33</b>   | <b>36</b>   | <b>96</b>     | <b>15</b>  | <b>19</b>   |
| <i>Avandia</i>                       | 408          | 23         | 26          | 315          | 25          | 27          | 33           | 14          | 14          | 60            | 19         | 28          |
| <i>Avandamet</i>                     | 64           | >100       | >100        | 37           | >100        | >100        | 21           | 100         | >100        | 6             | >100       | 100         |
| <i>Avandaryl</i>                     | 5            | -          | -           | 4            | -           | -           | -            | -           | -           | 1             | -          | -           |
| <i>Bonviva/Boniva</i>                | 19           | >100       | >100        | 16           | >100        | >100        | 3            | -           | -           | -             | -          | -           |
| <b>VACCINES</b>                      | <b>387</b>   | <b>17</b>  | <b>20</b>   | <b>90</b>    | <b>35</b>   | <b>36</b>   | <b>175</b>   | <b>16</b>   | <b>19</b>   | <b>122</b>    | <b>8</b>   | <b>12</b>   |
| <i>Hepatitis</i>                     | 121          | 3          | 4           | 42           | 24          | 27          | 58           | (11)        | (6)         | 21            | 10         | -           |
| <i>Infanrix/Pediarix</i>             | 129          | 38         | 40          | 39           | 25          | 22          | 76           | 45          | 49          | 14            | 44         | 56          |
| <i>Boostrix</i>                      | 15           | >100       | >100        | 9            | >100        | >100        | 4            | 100         | 100         | 2             | 100        | 100         |
| <b>CARDIOVASCULAR AND UROGENITAL</b> | <b>383</b>   | <b>21</b>  | <b>23</b>   | <b>228</b>   | <b>36</b>   | <b>36</b>   | <b>102</b>   | <b>(5)</b>  | <b>(2)</b>  | <b>53</b>     | <b>30</b>  | <b>33</b>   |
| <i>Coreg</i>                         | 160          | 29         | 28          | 158          | 28          | 27          | -            | -           | -           | 2             | 100        | 100         |
| <i>Levitra</i>                       | 9            | (18)       | (18)        | 8            | -           | -           | 1            | -           | -           | -             | -          | -           |
| <i>Avodart</i>                       | 51           | 79         | 82          | 30           | >100        | >100        | 17           | 14          | 21          | 4             | 100        | 100         |
| <i>Arixtra</i>                       | 13           | >100       | >100        | 6            | 50          | 50          | 6            | >100        | >100        | 1             | 100        | >100        |
| <i>Fraxiparine</i>                   | 56           | -          | 2           | -            | -           | -           | 47           | -           | 4           | 9             | -          | (10)        |
| <b>ANTI-BACTERIALS</b>               | <b>326</b>   | <b>(8)</b> | <b>(6)</b>  | <b>46</b>    | <b>(16)</b> | <b>(16)</b> | <b>149</b>   | <b>(7)</b>  | <b>(4)</b>  | <b>131</b>    | <b>(5)</b> | <b>(5)</b>  |
| <i>Augmentin</i>                     | 134          | (15)       | (13)        | 18           | (38)        | (38)        | 64           | (10)        | (9)         | 52            | (9)        | (5)         |
| <i>Zinnat/Ceftin</i>                 | 37           | (10)       | (8)         | 2            | 100         | 100         | 18           | (18)        | (18)        | 17            | (6)        | -           |
| <b>ONCOLOGY AND EMESIS</b>           | <b>289</b>   | <b>15</b>  | <b>17</b>   | <b>226</b>   | <b>21</b>   | <b>23</b>   | <b>42</b>    | <b>-</b>    | <b>-</b>    | <b>21</b>     | <b>(9)</b> | <b>(5)</b>  |
| <i>Zofran</i>                        | 229          | 11         | 12          | 183          | 18          | 19          | 31           | (9)         | (3)         | 15            | (6)        | (17)        |
| <i>Hycamtin</i>                      | 28           | 22         | 22          | 17           | 21          | 21          | 9            | 14          | 29          | 2             | 50         | -           |
| <b>OTHER</b>                         | <b>238</b>   | <b>(9)</b> | <b>(10)</b> | <b>22</b>    | <b>31</b>   | <b>38</b>   | <b>64</b>    | <b>(20)</b> | <b>(20)</b> | <b>152</b>    | <b>(8)</b> | <b>(10)</b> |
| <i>Zantac</i>                        | 61           | 2          | 2           | 19           | 46          | 46          | 14           | (13)        | (7)         | 28            | (9)        | (13)        |
|                                      | <b>5,021</b> | <b>10</b>  | <b>11</b>   | <b>2,554</b> | <b>18</b>   | <b>20</b>   | <b>1,404</b> | <b>-</b>    | <b>2</b>    | <b>1,063</b>  | <b>6</b>   | <b>7</b>    |

Pharmaceutical turnover includes co-promotion income.

**PHARMACEUTICAL TURNOVER**  
Six months ended 30th June 2006

|                                      | Total         |             |            | USA          |             |             | Europe       |             |             | International |            |            |
|--------------------------------------|---------------|-------------|------------|--------------|-------------|-------------|--------------|-------------|-------------|---------------|------------|------------|
|                                      | £m            | CER%        | £%         | £m           | CER%        | £%          | £m           | CER%        | £%          | £m            | CER%       | £%         |
| <b>RESPIRATORY</b>                   | <b>2,541</b>  | <b>2</b>    | <b>5</b>   | <b>1,252</b> | <b>-</b>    | <b>5</b>    | <b>865</b>   | <b>3</b>    | <b>3</b>    | <b>424</b>    | <b>7</b>   | <b>12</b>  |
| <i>Seretide/Advair</i>               | 1,638         | 12          | 16         | 913          | 12          | 18          | 569          | 11          | 12          | 156           | 16         | 22         |
| <i>Flixotide/Flovent</i>             | 342           | 6           | 9          | 155          | 18          | 24          | 92           | (6)         | (5)         | 95            | 1          | 4          |
| <i>Serevent</i>                      | 148           | (11)        | (10)       | 44           | (16)        | (12)        | 72           | (13)        | (13)        | 32            | 3          | 3          |
| <i>Flixonase/Flonase</i>             | 199           | (39)        | (38)       | 128          | (47)        | (45)        | 30           | (9)         | (9)         | 41            | (26)       | (23)       |
| <b>CENTRAL NERVOUS</b>               | <b>1,814</b>  | <b>15</b>   | <b>19</b>  | <b>1,267</b> | <b>27</b>   | <b>34</b>   | <b>316</b>   | <b>(14)</b> | <b>(13)</b> | <b>231</b>    | <b>7</b>   | <b>8</b>   |
| <i>Seroxat/Paxil</i>                 | 320           | -           | 1          | 93           | 13          | 16          | 79           | (20)        | (20)        | 148           | 8          | 8          |
| <i>Paxil IR</i>                      | 232           | (6)         | (6)        | 14           | (18)        | (18)        | 79           | (19)        | (19)        | 139           | 6          | 5          |
| <i>Paxil CR</i>                      | 88            | 22          | 29         | 79           | 21          | 25          |              |             |             | 9             | 75         | >100       |
| <i>Wellbutrin</i>                    | 454           | 31          | 38         | 445          | 31          | 37          | 1            | -           | -           | 8             | 60         | 60         |
| <i>Wellbutrin IR, SR</i>             | 51            | 9           | 13         | 45           | 5           | 10          | 1            | -           | -           | 5             | 67         | 67         |
| <i>Wellbutrin XL</i>                 | 403           | 35          | 41         | 400          | 35          | 41          |              |             |             | 3             | 50         | 50         |
| <i>Imigran/Imitrex</i>               | 357           | 4           | 9          | 269          | 9           | 14          | 67           | (4)         | (4)         | 21            | (17)       | (13)       |
| <i>Lamictal</i>                      | 482           | 13          | 17         | 360          | 32          | 38          | 94           | (25)        | (25)        | 28            | -          | 8          |
| <i>Requip</i>                        | 122           | 84          | 91         | 78           | >100        | >100        | 39           | 22          | 22          | 5             | 25         | 25         |
| <b>ANTI-VIRALS</b>                   | <b>1,418</b>  | <b>11</b>   | <b>15</b>  | <b>682</b>   | <b>7</b>    | <b>13</b>   | <b>427</b>   | <b>10</b>   | <b>11</b>   | <b>309</b>    | <b>22</b>  | <b>26</b>  |
| <b>HIV</b>                           | <b>792</b>    | <b>3</b>    | <b>6</b>   | <b>364</b>   | <b>(5)</b>  | <b>-</b>    | <b>326</b>   | <b>7</b>    | <b>8</b>    | <b>102</b>    | <b>18</b>  | <b>23</b>  |
| <i>Combivir</i>                      | 284           | (5)         | (1)        | 125          | (14)        | (9)         | 117          | 1           | 1           | 42            | 15         | 24         |
| <i>Trizivir</i>                      | 144           | (6)         | (3)        | 75           | (9)         | (5)         | 61           | (3)         | (3)         | 8             | -          | 14         |
| <i>Eпивir</i>                        | 113           | (19)        | (16)       | 38           | (27)        | (22)        | 51           | (19)        | (19)        | 24            | -          | 9          |
| <i>Ziagen</i>                        | 61            | (14)        | (12)       | 25           | (14)        | (11)        | 21           | (30)        | (30)        | 15            | 27         | 36         |
| <i>Agenerase, Lexiva</i>             | 65            | 31          | 35         | 37           | 20          | 23          | 24           | 60          | 60          | 4             | -          | 33         |
| <i>Epzicom/Kivexa</i>                | 109           | >100        | >100       | 61           | 76          | 85          | 42           | >100        | >100        | 6             | >100       | >100       |
| <b>Herpes</b>                        | <b>481</b>    | <b>19</b>   | <b>23</b>  | <b>296</b>   | <b>28</b>   | <b>34</b>   | <b>72</b>    | <b>3</b>    | <b>3</b>    | <b>113</b>    | <b>10</b>  | <b>12</b>  |
| <i>Valtrex</i>                       | 418           | 23          | 28         | 292          | 28          | 34          | 54           | 10          | 10          | 72            | 19         | 22         |
| <i>Zovirax</i>                       | 63            | (5)         | (5)        | 4            | 33          | 33          | 18           | (14)        | (14)        | 41            | (2)        | (2)        |
| <i>Zeffix</i>                        | 78            | 14          | 18         | 6            | -           | -           | 11           | -           | -           | 61            | 18         | 24         |
| <i>Relenza</i>                       | 24            | >100        | >100       | 1            | -           | -           | 15           | -           | -           | 8             | >100       | >100       |
| <b>METABOLIC</b>                     | <b>963</b>    | <b>29</b>   | <b>35</b>  | <b>667</b>   | <b>32</b>   | <b>38</b>   | <b>119</b>   | <b>39</b>   | <b>40</b>   | <b>177</b>    | <b>16</b>  | <b>22</b>  |
| <i>Avandia</i>                       | 752           | 26          | 33         | 580          | 29          | 35          | 65           | 18          | 18          | 107           | 18         | 29         |
| <i>Avandamet</i>                     | 92            | 24          | 28         | 41           | (20)        | (16)        | 40           | >100        | >100        | 11            | 57         | 57         |
| <i>Avandaryl</i>                     | 17            | -           | -          | 16           | -           | -           |              |             |             | 1             | -          | -          |
| <i>Bonviva/Boniva</i>                | 34            | >100        | >100       | 30           | >100        | >100        | 4            | -           | -           | -             | -          | -          |
| <b>VACCINES</b>                      | <b>753</b>    | <b>29</b>   | <b>32</b>  | <b>173</b>   | <b>38</b>   | <b>44</b>   | <b>340</b>   | <b>30</b>   | <b>30</b>   | <b>240</b>    | <b>22</b>  | <b>27</b>  |
| <i>Hepatitis</i>                     | 237           | 10          | 13         | 79           | 25          | 34          | 113          | 1           | 3           | 45            | 10         | 10         |
| <i>Infanrix/Pediarix</i>             | 253           | 45          | 49         | 80           | 28          | 33          | 144          | 57          | 58          | 29            | 42         | 53         |
| <i>Boostrix</i>                      | 24            | >100        | >100       | 14           | >100        | >100        | 7            | >100        | >100        | 3             | 50         | 50         |
| <b>CARDIOVASCULAR AND UROGENITAL</b> | <b>809</b>    | <b>25</b>   | <b>30</b>  | <b>522</b>   | <b>44</b>   | <b>52</b>   | <b>198</b>   | <b>(5)</b>  | <b>(4)</b>  | <b>89</b>     | <b>21</b>  | <b>25</b>  |
| <i>Coreg</i>                         | 385           | 41          | 48         | 382          | 42          | 49          |              |             |             | 3             | -          | -          |
| <i>Levitra</i>                       | 20            | (10)        | (5)        | 18           | -           | 5           | 1            | (50)        | (50)        | 1             | -          | -          |
| <i>Avodart</i>                       | 98            | 76          | 81         | 58           | >100        | >100        | 33           | 27          | 27          | 7             | 50         | 75         |
| <i>Arixtra</i>                       | 24            | >100        | >100       | 13           | 100         | >100        | 10           | >100        | >100        | 1             | >100       | >100       |
| <i>Fraxiparine</i>                   | 107           | (2)         | -          |              |             |             | 91           | -           | 1           | 16            | (12)       | (6)        |
| <b>ANTI-BACTERIALS</b>               | <b>704</b>    | <b>(10)</b> | <b>(8)</b> | <b>108</b>   | <b>(21)</b> | <b>(18)</b> | <b>329</b>   | <b>(14)</b> | <b>(13)</b> | <b>267</b>    | <b>-</b>   | <b>4</b>   |
| <i>Augmentin</i>                     | 304           | (14)        | (12)       | 49           | (36)        | (35)        | 147          | (13)        | (13)        | 108           | (1)        | 4          |
| <i>Zinnat/Ceftin</i>                 | 87            | (18)        | (15)       | 6            | 50          | 50          | 44           | (31)        | (31)        | 37            | -          | 9          |
| <b>ONCOLOGY AND EMESIS</b>           | <b>577</b>    | <b>14</b>   | <b>19</b>  | <b>451</b>   | <b>21</b>   | <b>27</b>   | <b>83</b>    | <b>(2)</b>  | <b>(2)</b>  | <b>43</b>     | <b>(5)</b> | <b>-</b>   |
| <i>Zofran</i>                        | 459           | 12          | 17         | 364          | 18          | 24          | 61           | (8)         | (6)         | 34            | (6)        | (3)        |
| <i>Hycamtin</i>                      | 57            | 15          | 19         | 37           | 13          | 19          | 16           | 14          | 14          | 4             | 33         | 33         |
| <b>OTHER</b>                         | <b>487</b>    | <b>(8)</b>  | <b>(6)</b> | <b>47</b>    | <b>33</b>   | <b>42</b>   | <b>122</b>   | <b>(25)</b> | <b>(24)</b> | <b>318</b>    | <b>(3)</b> | <b>(2)</b> |
| <i>Zantac</i>                        | 126           | 4           | 6          | 40           | 50          | 54          | 28           | (10)        | (10)        | 58            | (8)        | (6)        |
|                                      | <b>10,066</b> | <b>10</b>   | <b>14</b>  | <b>5,169</b> | <b>17</b>   | <b>23</b>   | <b>2,799</b> | <b>1</b>    | <b>1</b>    | <b>2,098</b>  | <b>9</b>   | <b>12</b>  |

Pharmaceutical turnover includes co-promotion income.

**INCOME STATEMENT**  
**Three months ended 30th June 2006**

|   | Q2 2006<br>£m | Q2 2005<br>£m | Growth<br>CER% | £%        |
|---|---------------|---------------|----------------|-----------|
| Turnover:   |               |               |                |           |
| Pharmaceuticals   | 5,021         | 4,505         | 10             | 11        |
| Consumer Healthcare   | 790           | 741           | 5              | 7         |
| <b>TURNOVER</b>   | <b>5,811</b>  | <b>5,246</b>  | <b>9</b>       | <b>11</b> |
| Cost of sales   | (1,209)       | (1,155)       | 3              | 5         |
| Gross profit  | 4,602         | 4,091         | 11             | 12        |
| Selling, general and administration                         | (1,883)       | (1,681)       | 8              | 12        |
| Research and development                                    | (853)         | (702)         | 20             | 22        |
| Other operating income                                      | 45            | 3             |                |           |
| Operating profit:   |               |               |                |           |
| Pharmaceuticals   | 1,748         | 1,540         | 15             | 14        |
| Consumer Healthcare   | 163           | 171           | (6)            | (5)       |
| <b>OPERATING PROFIT</b>                                     | <b>1,911</b>  | <b>1,711</b>  | <b>13</b>      | <b>12</b> |
| Finance income  | 67            | 56            |                |           |
| Finance expense   | (93)          | (115)         |                |           |
| Share of after tax profits of associates and joint ventures | 12            | 10            |                |           |
| <b>PROFIT BEFORE TAXATION</b>                               | <b>1,897</b>  | <b>1,662</b>  | <b>15</b>      | <b>14</b> |
| Taxation  | (560)         | (473)         |                |           |
| <i>Tax rate %</i>   | <i>29.5%</i>  | <i>28.5%</i>  |                |           |
| <b>PROFIT AFTER TAXATION FOR THE PERIOD</b>                 | <b>1,337</b>  | <b>1,189</b>  | <b>14</b>      | <b>12</b> |
| Profit attributable to minority interests                   | 22            | 31            |                |           |
| Profit attributable to shareholders                         | 1,315         | 1,158         |                |           |
|   | <b>1,337</b>  | <b>1,189</b>  |                |           |
| <b>EARNINGS PER SHARE</b>                                   | <b>23.3p</b>  | <b>20.4p</b>  | <b>15</b>      | <b>14</b> |
| Diluted earnings per share                                  | <b>23.0p</b>  | <b>20.2p</b>  |                |           |

**INCOME STATEMENT**  
**Six months ended 30th June 2006**

|   | H1 2006<br>£m  | H1 2005<br>£m | Growth<br>CER% | £% |
|---|----------------|---------------|----------------|----|
| Turnover:   |                |               |                |    |
| Pharmaceuticals   | <b>10,066</b>  | 8,844         | 10             | 14 |
| Consumer Healthcare   | <b>1,558</b>   | 1,438         | 6              | 8  |
| <b>TURNOVER</b>   | <b>11,624</b>  | 10,282        | 9              | 13 |
| Cost of sales   | <b>(2,343)</b> | (2,282)       | 1              | 3  |
| Gross profit  | <b>9,281</b>   | 8,000         | 12             | 16 |
| Selling, general and administration                         | <b>(3,706)</b> | (3,326)       | 6              | 11 |
| Research and development                                    | <b>(1,606)</b> | (1,365)       | 15             | 18 |
| Other operating income                                      | <b>116</b>     | 149           |                |    |
| Operating profit:   |                |               |                |    |
| Pharmaceuticals   | <b>3,782</b>   | 3,166         | 15             | 19 |
| Consumer Healthcare   | <b>303</b>     | 292           | 1              | 4  |
| <b>OPERATING PROFIT</b>                                     | <b>4,085</b>   | 3,458         | 14             | 18 |
| Finance income  | <b>140</b>     | 105           |                |    |
| Finance expense   | <b>(185)</b>   | (213)         |                |    |
| Share of after tax profits of associates and joint ventures | <b>27</b>      | 23            |                |    |
| <b>PROFIT BEFORE TAXATION</b>                               | <b>4,067</b>   | 3,373         | 16             | 21 |
| Taxation  | <b>(1,200)</b> | (961)         |                |    |
| <i>Tax rate %</i>   | <b>29.5%</b>   | 28.5%         |                |    |
| <b>PROFIT AFTER TAXATION FOR THE PERIOD</b>                 | <b>2,867</b>   | 2,412         | 15             | 19 |
| Profit attributable to minority interests                   | <b>50</b>      | 52            |                |    |
| Profit attributable to shareholders                         | <b>2,817</b>   | 2,360         |                |    |
|   | <b>2,867</b>   | 2,412         |                |    |
| <b>EARNINGS PER SHARE</b>                                   | <b>49.8p</b>   | 41.5p         | 16             | 20 |
| Diluted earnings per share                                  | <b>49.2p</b>   | 41.2p         |                |    |

**CONSUMER HEALTHCARE TURNOVER**  
**Three months ended 30th June 2006**

|                                   | Q2 2006<br>£m | Growth<br>CER% | £%       |
|-----------------------------------|---------------|----------------|----------|
| <b>Over-the-counter medicines</b> | <b>365</b>    | <b>3</b>       | <b>5</b> |
| Analgesics                        | 99            | 13             | 13       |
| Dermatological                    | 45            | (4)            | (2)      |
| Gastrointestinal                  | 63            | 2              | 3        |
| Respiratory tract                 | 35            | 10             | 17       |
| Smoking control                   | 84            | 8              | 8        |
| Natural wellness support          | 30            | (9)            | (9)      |
| <b>Oral care</b>                  | <b>253</b>    | <b>7</b>       | <b>9</b> |
| <b>Nutritional healthcare</b>     | <b>172</b>    | <b>7</b>       | <b>6</b> |
| <b>Total</b>                      | <b>790</b>    | <b>5</b>       | <b>7</b> |

**CONSUMER HEALTHCARE TURNOVER**  
**Six months ended 30th June 2006**

|                                   | Q2 2006<br>£m | Growth<br>CER% | £%        |
|-----------------------------------|---------------|----------------|-----------|
| <b>Over-the-counter medicines</b> | <b>739</b>    | <b>3</b>       | <b>7</b>  |
| Analgesics                        | 194           | 10             | 13        |
| Dermatological                    | 85            | (4)            | -         |
| Gastrointestinal                  | 128           | 2              | 8         |
| Respiratory tract                 | 76            | 9              | 12        |
| Smoking control                   | 177           | 6              | 10        |
| Natural wellness support          | 64            | (5)            | (3)       |
| <b>Oral care</b>                  | <b>495</b>    | <b>7</b>       | <b>10</b> |
| <b>Nutritional healthcare</b>     | <b>324</b>    | <b>8</b>       | <b>9</b>  |
| <b>Total</b>                      | <b>1,558</b>  | <b>6</b>       | <b>8</b>  |